Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) has issued an update.
Fuso Pharmaceutical Industries, Ltd. has filed an appeal with the Supreme Court following a judgment in a patent infringement lawsuit involving their oral antipruritus agent, Nalfurafine Hydrochloride OD Tablets. The Intellectual Property High Court had previously ruled in favor of Toray Industries, Inc., ordering Fuso to pay over 7 billion yen in damages. The company maintains that their product does not infringe on Toray’s patent rights and is seeking a reversal of the decision.
More about Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is listed on the Tokyo Stock Exchange Prime Market and is known for its oral antipruritus agent, among other products.
Average Trading Volume: 25,406
Technical Sentiment Signal: Sell
Current Market Cap: Yen18.76B
Learn more about 4538 stock on TipRanks’ Stock Analysis page.